Entera Bio Stock Analysis

Entera Stock Analysis Notes

About 25.0% of the company shares are held by company insiders. The book value of Entera Bio was currently reported as 0.33. The company recorded a loss per share of 0.24. Entera Bio had not issued any dividends in recent years. Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people. To learn more about Entera Bio call Miranda MBA at 972 2 532 7151 or check out https://www.enterabio.com.

Entera Bio Investment Alerts

Entera Largest EPS Surprises

View All Earnings Estimates

Entera Stock Institutional Investors

Note, although Entera Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Entera Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 68.79 M.

Entera Profitablity

Management Efficiency

Entera Bio has return on total asset (ROA) of (0.538) % which means that it has lost $0.538 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9943) %, meaning that it created substantial loss on money invested by shareholders. Entera Bio's management efficiency ratios could be used to measure how well Entera Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.96 in 2026. Return On Capital Employed is likely to drop to -1.41 in 2026. At this time, Entera Bio's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 14.2 M in 2026, whereas Other Current Assets are likely to drop slightly above 159 K in 2026.

Technical Drivers

As of the 15th of February 2026, Entera Bio shows the Mean Deviation of 4.25, standard deviation of 6.24, and Variance of 38.94. Entera Bio technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Entera Bio Price Movement Analysis

Entera Bio Insider Trading Activities

Entera Bio Outstanding Bonds

Entera Bio Predictive Daily Indicators

Entera Bio Forecast Models

Entera Bio's time-series forecasting models are one of many Entera Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Entera Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Entera Bio Bond Ratings

Entera Bio financial ratings play a critical role in determining how much Entera Bio have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Entera Bio's borrowing costs.

Entera Bio Debt to Cash Allocation

Entera Bio currently holds 272 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Entera Bio has a current ratio of 10.67, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Entera Bio's use of debt, we should always consider it together with its cash and equity.

Entera Bio Total Assets Over Time

Entera Bio Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Entera Bio uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Entera Bio Debt Ratio

3.16

It appears most of the Entera Bio's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Entera Bio's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Entera Bio, which in turn will lower the firm's financial flexibility.

Entera Bio Corporate Bonds Issued

Entera Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Entera Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Entera shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Entera Bio. By using and applying Entera Stock analysis, traders can create a robust methodology for identifying Entera entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Entera analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Entera analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Entera Bio stock analysis indicators help investors evaluate how Entera Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Entera Bio shares will generate the highest return on investment. By understating and applying Entera Bio stock analysis, traders can identify Entera Bio position entry and exit signals to maximize returns.

When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.